Key Highlights
- Partnership to enhance value-based care by reducing costs and improving outcomes.
- Medication Therapy Optimization (MTO) platform to assist physicians in prescribing decisions.
- Successful implementation saw 78% of patients receiving clinically actionable guidance.
- Personalized medicine focus with significant genetic and drug-drug contraindications identified.
- Positive patient feedback with over 80% finding pharmacogenomics test results helpful.
Source: Business Wire
Notable Quotes
- “Imperium Health is an ideal partner for DecisionRx because it shares our commitment to value-based care, and there is no denying the value – approximately $3,600 per engaged Medicare patient per year – created by Medication Therapy Optimization.” — James Wallace, CEO at DecisionRx
- “My personal experience confirms that combining pharmacogenetic testing and comprehensive medication review by a trained clinical pharmacist has a meaningful impact on patient outcomes and total cost of care.” — Jerome Dixon, DO, Medical Director at Imperium Clinical Partners
SoHC's Take
The partnership between DecisionRx and Imperium Health represents a significant step forward in the evolution of value-based care. By integrating DecisionRx’s advanced Medication Therapy Optimization platform, Imperium Health can offer a higher level of personalized care, addressing the unique genetic makeup and medication responses of individual patients. This collaboration is not only a testament to the power of pharmacogenomics in modern medicine but also highlights the critical need for innovative solutions to reduce healthcare costs while improving patient outcomes. As healthcare systems increasingly move towards value-based models, partnerships like this will become essential in providing efficient, effective, and patient-centered care.
